Use of recombinant human erythropoietin outside the setting of uremia

Blood

Volumn 89, Issue 12, 1997, Pages 4248-4267

  Cazzola, Mario ^a   Mercuriali, Francesco ^c   Brugnara, Carlo ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERROUS SULFATE; IRON; IRON DEXTRAN; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ANEMIA; BLOOD AUTOTRANSFUSION; BONE MARROW TRANSPLANTATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; ERYTHROPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON THERAPY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN DEFECT; RETICULOCYTE COUNT; REVIEW; SEIZURE; SUBCUTANEOUS DRUG ADMINISTRATION; UREMIA;

EID: 0030974613     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.12.4248     Document Type: Review

References (182)

1. Eschbach JW: Erythropoietin: The promise and the facts. Kidney Int 45:70, 1994 (suppl 44)
2. Rao DS, Shih M-S, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328:171, 1993
3. Ifudu O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin patients with end-stage renal disease. N Engl J Med 334:420, 1996
4. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, van Stone JC, van Wyck DB, Zuckerman K, Adamson JW: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992, 1989
5. McMahon LP, Dawborn JK: Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 12:162, 1992
6. Bergström J: New aspects of erythropoietin treatment. J Intern Med 233:445, 1993
7. Jacobson LO, Goldwasser E, Fried W, Plzak L: Role of the kidney in erythropoiesis. Nature 179:633, 1957
8. Lacombe C, Da Silva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P: Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidneys. J Clin Invest 81:620, 1988
9. Koury ST, Bondurant MC, Koury MJ: Localization of erythropoietin synthetizing cells in murine kidneys by in situ hybridization. Blood 71:524, 1988
10. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE: Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization. Correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 74:645, 1989
11. Gaines Das RE, Milne A, Rowley M, Gordon-Smith EC, Cotes PM: Serum immunoreactive erythropoietin in patients with idiopathic aplastic and Fanconi's anaemia. Br J Haematol 82:601, 1992
12. Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Goldberg MA: Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 76:2354, 1990
13. Birgegård G, Wide L, Simonssson B: Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol 72:462, 1989
14. Kendall RG, Cavill I, Norfolk DR: Serum erythropoietin levels during haematinic therapy. Br J Haematol 81:630, 1992 (letter)
15. Cazzola M, Beguin Y: New tools for clinical evaluation of erythropoiesis and iron status in man. Br J Haematol 80:278, 1992
16. Cazzola M, Guarnone R, Beguin Y: Red cell precursors mass as an independent determinant of serum erythropoietin level. Blood 88:348a, 1996 (abstr, suppl 1)
17. Faquin WC, Schneider TJ, Goldberg MA: Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79:1987, 1992
18. Jelkmann W, Pagel H, Wolff M, Fandrey J: Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 50:301, 1992
19. Means RT, Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80:1639, 1992
20. Cazzola M, Ponchio L, de Benedetti F, Ravelli A, Rosti V, Beguin Y, Invernizzi R, Barosi G, Martini A: Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 87:4824, 1996
21. Singh A, Eckardt KU, Zimmermann A, Götz KH, Hamann M, Ratcliffe PJ, Kurtz A, Reinhart WH: Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 91:251, 1993
22. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689, 1990
23. Smith DH, Goldwasser E, Vokes EE: Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer 68:1101, 1991
24. Wood PA, Hrushesky WJ: Cisplatin-associated anemia: An erythropoietin deficiency syndrome. J Clin Invest 95:1650, 1995
25. Vannucchi AM, Grossi A, Bosi A, Rafanelli D, Guidi S, Saccardi R, Alterini R, Rossi Ferrini P: Impaired erythropoietin production in mice treated with cyclosporin-A. Blood 78:1615, 1991
26. Schrezenmeier H, Noé G, Raghavacar A, Rich IN, Heimpel H, Kubanek B: Serum erythropoietin and serum transferrin receptor levels in aplastic anaemia. Br J Haematol 88:286, 1994
27. Bakris GI, Sauter ER, Hussey JL, Fisher JW, Gaber AO, Winsett R: Effect of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 323:86, 1990
28. Wang Z, Goldberg M, Scadden D: HIV-1 suppresses erythropoietin production in vitro. Exp Hematol 21:683, 1993
29. D'Andrea AD, Zon LI: Erythropoietin receptor. Subunit structure and activation. J Clin Invest 86:681, 1990
30. Sawada K, Krantz SB, Sawyer ST, Civin CI: Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells. J Cell Physiol 137:337, 1988
31. Sawada K, Krantz SB, Dai CH, Koury ST, Horn ST, Glick AD, Civin CI: Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors. J Cell Physiol 142:219, 1990
32. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T: Erythropoietin receptor characteristics on primary human erythroid cells. Blood 77:2583, 1991
33. Koury MJ, Bondurant MC: Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248:378, 1990
34. Spivak JL, Pham T, Isaacs M, Hankins WD: Erythropoietin is both a mitogen and a survival factor. Blood 77:1228, 1991
35. Muta K, Krantz SB, Bondurant MC, Wickrema A: Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 94:34, 1994
36. Kelley LL, Koury MJ, Bondurant MC, Koury ST, Sawyer ST, Wickrema A: Survival and death of individual proerythroblasts results from differing erythropoietin sensitivities: A mechanism for controlled rates of erythrocyte production. Blood 82:2340, 1993
37. Wu H, Liu X, Jaenisch R, Lodish HF: Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83:59, 1995
38. Silva M, Grillot D, Benito A, Richard C, Nuñez G, Fernández-Luna JL: Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-XL and bcl-2. Blood 88:1576, 1996
39. Koury MJ, Bondurant MC: Control of red cell production: The role of programmed cell death (apoptosis) and erythropoietin. Transfusion 30:673, 1990
40. Major A, Bauer C, Breymann C, Huch A, Huch R: Rh-erythropoietin stimulates immature reticulocyte release in man. Br J Haematol 87:605, 1994
41. McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL: Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injection in healthy volunteers. Blood 76:1718, 1990
42. Skikne BS, Cook JD: Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 120:746, 1992
43. Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G: Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin. Br J Haematol 89:17, 1995
44. Barosi G: Inadequate erythropoietin response to anemia. Definition and clinical relevance. Ann Hematol 68:215, 1994
45. Cotes PM: Anomalies in circulating erythropoietin levels, in Rich IN, Lappin TRJ (eds): Molecular, Cellular and Developmental Biology of Erythropoietin and Erythropoiesis. New York, NY, New York Academy of Sciences, 1994, p 103
46. Storring PL, Gaines Das RE: The international standard for recombinant DNA-derived erythropoietin: Collaborative study on four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol 134:459, 1992
47. Beguin Y, Clemons G, Pootrakul P, Fillet G: Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81:1067, 1993
48. Salmonson T, Danielson BG, Wikström B: The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 29:709, 1990
49. Erslev A: Erythropoietin. N Engl J Med 324:1339, 1991
50. Cazzola M, Ponchio L, Beguin Y, Rosti V, Bergamaschi G, Liberato NL, Fregoni V, Nalli G, Barosi G, Ascari E: Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 79:29, 1992
51. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jäger G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B: Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin lymphoma: Dose finding and identification of predictors of response. Blood 86:4446, 1995
52. Breymann C, Bauer C, Major A, Zimmermann R, Gautschi K, Huch A, Huch R: Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers. Br J Haematol 92:295, 1996
53. Henry D, Abels R, Larholt K: Prediction of response to recombinant human erythropoietin (r-HuEPO/Epoetin-a) therapy in cancer patients (letter). Blood 85:1676, 1995
54. Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y: Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81:434, 1996
55. Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G: Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 82:2010, 1993
56. Finch CA, Huebers HA: Perspectives in iron metabolism. N Engl J Med 306:1520, 1982
57. Cazzola M, Pootrakul P, Bergamaschi G, Huebers HA, Eng M, Finch CA: Adequacy of iron supply for erythropoiesis: In vivo observations in humans. J Lab Clin Med 110:734, 1987
58. Brugnara C, Chambers LA, Malynn E, Goldberg MA, Kruskall MS: Red cell regeneration induced by subcutaneous recombinant erythropoietin: Iron-deficient erythropoiesis in iron-replete subjects. Blood 81:956, 1993
59. Biesma DH, van de Wiel A, Beguin Y, Kraaijenhagen RJ, Marx JJM: Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. Eur J Clin Invest 24:426, 1994
60. Brugnara C, Colella GM, Cremins J, Langley RC, Schneider TJ, Rutherford CJ, Goldberg MA: Effects of subcutaneous recombinant human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron deficient erythropoiesis. J Lab Clin Med 123:660, 1994
61. Mercuriali F, Zanella A, Barosi G, Inghilleri G, Biffi E, Vinci A, Colotti MT: Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 33:55, 1993
62. Macdougall IC, Cavill I, Hulme B, Bain B, McGregory E, McKay P, Sanders E, Coles GA, Williams JD: Detection of functional iron deficiency during erythropoietin treatment: A new approach. Br Med J 304:225, 1992
63. Biesma DH, Bronkhorst PJH, de Groot PG, van de Wiel A, Kraaijenhagen RJ, Marx JJM: The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors. J Lab Clin Med 124:42, 1994
64. Peces R, de la Torre R, Alcázar R, Urra JM: Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335:523, 1996 (letter)
65. Spivak JL: Recombinant human erythropoietin and its role in transfusion medicine. Transfusion 34:1, 1994
66. Williamson L: Homologous blood transfusion: the risk and alternatives. Br J Haematol 88:451, 1994
67. Thomas MJG, Gillon J, Desmond MJ: Consensus conference on autologous transfusion. Preoperative autologous donation. Transfusion 36:633, 1996
68. Gillon J, Thomas MJG, Desmond MJ: Consensus conference on autologous transfusion. Acute normovolaemic haemodilution. Transfusion 36:640, 1996
69. Desmond MJ, Thomas MJG, Gillon J, Fox MA: Consensus conference on autologous transfusion. Perioperative red cell salvage. Transfusion 36:644, 1996
70. Goodnough LT, Wassman J, Corlucci K, Chernosky A: Limitation to donating adequate autologous blood prior to elective orthopedic surgery. Arch Surg 124:494, 1989
71. Mercuriali F, Biffi E, Inghilleri G, Vinci A: Low haematocrit: Limiting factor in autologous blood predonation programme, in Castelli D, Genetet B, Habibi B, Nyddeger Y (eds): Transfusion in Europe, Proceedings of the First ISBT Regional Congress. Paris, France, Arnette, 1989, p 291
72. Goodnough LT, Brittenham GM: Limitations of the erythropoietic response to serial phlebotomy: Implications for autologous blood donor programs. J Lab Clin Med 115:28, 1990
73. Kickler TS, Spivak JL: Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA 260:65, 1988
74. Klein HG: Standards for Blood Banks and Transfusion Services (ed 17). Bethesda, MD, American Association of Blood Banks, 1996
75. Goodnough LT, Rudnick S, Price TH, Ballas SK, Collins ML, Crowley JP, Kosmin M, Kruskall MS, Lenes BA, Menitove JE, Silberstein LE, Smith KJ, Wallas CH, Abels R, Von Tress M: Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 321:1163, 1989
76. Kyo S, Omoto R, Hirashima K, Eguchi S, Fujita T: Effect of human recombinant erythropoietin on reduction of homologous blood transfusion in open-heart surgery. A Japanese multicenter study. Circulation 86:413, 1992 (suppl II)
77. Kulier AH, Gombotz H, Fuchs G, Vuckovic U, Metzler H: Subcutaneous recombinant human erythropoietin and autologous blood donation before coronary artery bypass surgery. Anesth Analg 76:102, 1993
78. Beris P, Mermillod B, Levy G, Laubriat M, Soulier Lauper M, Tullen E, Hugli A, Miescher PA: Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study. Vox Sang 65:212, 1993
79. Goodnough LT, Price TH, Friedman KD, Johnston M, Ciavarella D, Khan N, Sacher R, Vogler WR, Wissel M, Abels RI: A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: Dose, response, toxicity, and efficacy. Transfusion 34:66, 1994
80. Biesma DH, Marx JJM, Kraaijenhagen RJ, Franke W, Messinger D, van de Wiel A: Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet 344:367, 1994
81. Watanabe Y, Fuse K, Konishi T, Kobayasi T, Takazawa K, Konishi H, Shibata Y: Autologous blood transfusion with recombinant human erythropoietin in heart operations. Ann Thorac Surg 51:767, 1991
82. Biesma DH, Kraaijenhagen RJ, Marx JJ, van de Wiel A: The efficacy of subcutaneous recombinant human erythropoietin in the correction of phlebotomy-induced anemia in autologous blood donors. Transfusion 33:825, 1993
83. Biesma DH, Van de Wiel A, Beguin Y, Kraaijenhagen RJ, Marx JJ: Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. Eur J Clin Invest 24:426, 1994
84. Hayashi J, Kumon K, Takanashi S, Kawashima Y, Eguchi S, Takaku F, Yamamura H: Subcutaneous administration of recombinant human erythropoietin before cardiac surgery: A double-blind, multicenter trial in Japan. Transfusion 34:142, 1994
85. Braga M, Gianotti L, Vignali A, Gentilini O, Servida P, Bordignon C, Di Carlo V: Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. Br J Surg 82:1637, 1995
86. Mercuriali F, Gualtieri G, Sinigaglia L, Inghilleri G, Biffi E, Vinci A, Colotti MT, Barosi G, Lambertenghi deliliers G: Use of recombinant human erythropoietin to assist autologous blood donaon by anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Transfusion 34:501, 1994
87. Price TH, Goodnough LT, Vogler WR, Sacher RA, Hellman RM, Johnston MFM, Bolgiano DC, Abels RI: The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: A multicenter, randomized, double-blind, controlled trial. Transfusion 36:29, 1996
88. Goodnough LT, Price TH, Friedman KD, Johnston M, Ciavarella D, Khan N, Sacher R, Vogler WR, Wissel M, Abels RI: A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: Dose, response, toxicity, and efficacy. Transfusion 34:66, 1994
89. Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, Fink A, Brook R: The cost effectiveness of preoperative autologous blood donations. N Engl J Med 332:719, 1995
90. Birkmeyer JD, Goodnough LT, Aubuchon JP, Noordsij PG, Littenberg B: The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 33:544, 1993
91. Rutherford CJ, Kaplan HS: Autologous blood donation - Can we bank on it? N Engl J Med 332:740, 1995
92. Goldfinger D, Haimowitz M: Controversies in transfusion medicine: Is autologous blood transfusion worth the cost? Pro Transfusion 34:75, 1994
93. Biesma DH, Kraaijenhagen RJ, Dalmulder J, Marx JM, van De Wiel A: Recombinant human erythropoietin in autologous blood donors: A dose-finding study. Br J Haematol 86:30, 1994
94. Sans T, Bofill C, Joven J, Cliville X, Simo JM, Llobet X, Pero A, Galbany J: Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery. Transfusion 36:822, 1996
95. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V: The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell volume expansion in autologous blood donors for elective orthopedic operation. J Am Coll Surg 179:171, 1994
96. Adamson J: Perisurgical use of epoetin alfa in orthopedic surgery patients. Semin Hematol 33:55, 1996 (suppl 2)
97. Sparling EA, Nelson CL, Lavender R, Smith J: The use of erythropoietin in the management of Jehovah's witnesses who have revision total hip arthroplasty. J Bone Joint Surg 78-A:1548, 1996
98. Canadian Orthopedic Perioperative Erythropoietin Study Group: Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 341:1227, 1993
99. Mohandas K, Aledort L: Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 35:427, 1995
100. Fans PM, Ritter MA, Abels RI: The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group. J Bone Joint Surg Am 78:62, 1996
101. deAndrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC: Baseline hemoglobin as a predictor of risk of transfusion and response to Epoietin alfa in orthopedic surgery patients. Am J Orthoped 25:533, 1996
102. Heiss MM, Tarabichi A, Delanoff C, Allgayer H, Jauch KW, Hernandezrichter T, Mempel W, Beck KG, Schildberg FW, Messmer K: Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Surgery 119:523, 1996
103. Rutherford CJ, Schneider TJ, Dempsey H, Kirn D, Brugnara C, Goldberg MA: Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: The portance of iron availability in optimizing response. Am J Med 96:139, 1994
104. Goldberg MA, McCutchen JW, Jove M, Di Cesare P, Friedman RJ, Poss R, Guilfoyle M, Frei D, Young DC: A safety and efficacy comparison study of two dosing regimens of Epoietin alfa in patients undergoing major orthopedic surgery. Am J Orthoped 25:544, 1996
105. Heiss MM, Tarabichi A, Delanoff C, Allgayer H, Jauch KW, Hernandez-Richter T, Mempel W, Beck KG, Schildberg FW, Messmer K: Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Surgery 119:523, 1996
106. Weiskopf RB: Mathematical analysis of isovolemic hemodilution indicates that it can decrease the need for allogeneic blood transfusion. Transfusion 35:37, 1995
107. Brecher ME, Rosenfeld M: Mathematical and computer modeling of acute normovolemic hemodilution. Transfusion 34:176, 1994
108. Monk TG, Goodnough LT, Birkmeyer JD, Brecher ME, Catalona WJ: Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy. Transfusion 35:559, 1995
109. 108a. Kick O, Daniel E: Mathematical considerations in the practice of acute normovolemic dilution. Transfusion 34:141, 1997
110. 108b. Sowade O, Warnke H, Scigalla P, Sowade B, Franke W, Messinger D, Gross J: Avoidance of allogeneic blood transfusion by treatment with epoietin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood 89:411, 1997
111. Thompson JF: Intraoperative blood salvage. Haematol Rev 7:55, 1992
112. 109a. Sowade O, Gross J, Sowade B, Warnke H, Franke W, Messinger D, Scigalla P, Lun A, Glatzel E: Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open-heart surgery treated with epoietin beta. J Lab Clin Med 129:97, 1997
113. Atabek U, Alvarez R, Pello MJ, Alexander JB, Camishion RC, Curry C, Spence RK: Erythropoietin accelerates hematocrit recovery in post-surgical anemia. Am Surg 61:74, 1995
114. Messmer K: Consensus statement: Using epoetin alfa to decrease the risk of allogeneic blood transfusion in the surgical setting. Semin Hematol 33:78, 1996 (suppl 2)
115. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G: Recombinant human erythropoietin treatment in cis-platin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 12:1058, 1994
116. ten Bokkel-Huinink W: Controlled multicenter study of the influence of two different dosages of subcutaneous rhEPO on the development of anemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based combination chemotherapy, in Smyth JF, Boogaerts MA, Ehmer B (eds): rhErythropoietin in Cancer Supportive Treatment. New York, NY, Marcel Dekker, 1996, p 99
117. de Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, Testa N, Thatcher N: Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 13:1623, 1995
118. Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, Kurz RW: Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 36:155, 1996
119. Bilgrami S, Bartolomeo A, Synnot V, Rickels FR: Management of hemosiderosis complicated by coexistent anemia with rembinant human erythropoietin and phlebotomy. Acta Haematol 89:141, 1993
120. Anderson KE, Goerger DE, Carson RW, Lee A-MK, Stead RB: Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med 322:315, 1990
121. Stockman JA III, Garcia JF, Oski FA: The anemia of prematurity: Factors governing the erythropoietin response. N Engl J Med 296:647, 1977
122. Stockman JA III, Graeber JE, Clark DA, McClellan K, Garcia JF, Kavey RW: Anemia of prematurity: Determinants of the erythropoietin response. J Pediatr 105:786, 1984
123. Meyer MP, Meyer JH, Commerford A, Hann FM, Sive AA, Moller G, Jacobs P, Malan AF: Recombinant human erythropoietin in the treatment of the anemia of prematurity: Results of a double-blind, placebo-controlled study. Pediatrics 93:918, 1994
124. Maier RF, Obladen M, Scigalla P, Linderkamp O, Duc G, Hieronimi G, Halliday HL, Versmold HT, Moriette G, Jorch G, Verellen G, Semmekrot BA, Grauel EL, Holland BM, Wardrop CAJ: The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. N Engl J Med 330:1173, 1994
125. Shannon KM, Keith JF 3rd, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA, Gleason CA, Bifano EM, Millard DD, Davis CB, et al: Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 95:1, 1995
126. Soubasi V, Kremenopoulos G, Diamanti E, Tsantali C, Sarafidis K, Tsakiris D: Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. J Pediatr 127:291, 1995
127. Gumy-Pause F, Brighi L, Berner M, Bittar-Fulpius L, Wacker P, Halperin DS, Humbert J: Prevention of transfusions in the anemia of prematurity by high dose erythropoietin. Blood 88:145a, 1996 (abstr, suppl 1)
128. Ohls RK, Osborne KA, Christensen RD: Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: A randomized, placebo-controlled trial. J Pediatr 126:421, 1995
129. Fain J, Hilsenrath P, Widness JA, Strauss RG, Mutnick AH: A cost analysis comparing erythropoietin and red cell transfusions in the treatment of anemia of prematurity. Transfusion 35:936, 1995
130. Pincus T, Olsen NJ, Russell IJ, Wolfe F, Harris ER, Schnitzer TJ, Boccagno JA, Krantz SB: Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 89:161, 1990
131. Martini A, Ravelli A, Di Fuccia G, Rosti V, Cazzola M, Barosi G: Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 344:1052, 1994
132. Montecucco CM, Caporali R, Invernizzi R: Iron status in Still's disease. Lancet 345:58, 1995 (letter)
133. Salvarani C, Lasagni D, Casali B, Macchioni P, Boiardi L, Rossi F, Rivasi P, Portioli I: Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease. J Rheumatol 18:1168, 1991
134. Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, Gasche C, Lochs H, Raedler A: Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 334:619, 1996
135. Fischl M, Galpin JE, Levine JD, Groopman JE, Henry DH, Kennedy P, Miles S, Robbins W, Starrett B, Zalusky R, Abels RI, Tsai HC, Rudnick SA: Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 322:1488, 1990
136. Henry DH, Beall GN, Benson CA, Carey J, Cone LA, Eron LJ, Fiala M, Fischl M, Gabin SJ, Gottlieb MS, Galpin JE, Groopman JE, Hooton TM, Jemsek JG, Levine RL, Miles SA, Rinehart JJ, Rios A, Robbins WJ, Ruckdeschel JC, Smith JA, Spruance SL, Starrett B, Toney J, Zalusky R, Abels IRI, Bryant EC, Larholt KM, Sampson AR, Rudnick SA: Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infections and zidovudine therapy. Overview of four clinical trials. Ann Intern Med 117:739, 1992
137. Phair JP, Abels RI, McNeill MV, Sullivan DJ: Recombinant human erythropoietin treatment: Investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Arch Intern Med 153:2669, 1993
138. Rendo P, Freigerio D, Braier J, Donato H, Dreliehman G, Barboni G: Double-blind multicentric randomized study of recombinant human erythropoietin in HIV+ children with anemia treated with antiretrovirals. Blood 88:348a, 1996 (abstr, suppl 1)
139. Doll DC, Weiss RB: Neoplasia and the erythron, J Clin Oncol 3:429, 1993
140. Spivak JL: Recombinant human erythropoietin and the anemia of cancer. Blood 84:997, 1994
141. Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Müller G, Brune T, Kraemer H-P, Mertelsmann R: Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 8:956, 1990
142. Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, Mc-Evilly J-M, Jones RJ, Ratain MJ: Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 9:2021, 1991
143. Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, Jones RJ: Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 84:98, 1992
144. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G: Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. Br J Cancer 67:156, 1993
145. Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR, Salmon SE, Silver RT, Storniolo AM, Wampler GL, Dooley CM, Larholt KM, Nelson RA, Abels RI: Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85:801, 1993
146. Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB, Potish RA: Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 29:1079, 1994
147. Lavey RS, Dempsey WH: Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 27:1147, 1993
148. Bukowski R, Glaspy J, Steinberg D, Taylor CW, Vadhan-Raj S, Danna RP, Sarokan B, Lonczak L, McNeill M: Phase IV evaluation of clinical outcomes of Procrit® (Epoietin alfa) in anemic cancer patients receiving chemotherapy. Blood 84:129a, 1994 (abstr, suppl 1)
149. Quirt I, Couture F, Pichette R, Olweny C, White D, King M, Sawka C, Huan S, Clinch J, Lau C: The role of recombinant human erythropoietin in reducing red blood cell transfusions and maintaining quality of life in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy. Results of a randomized, double-blind, placebo-controlled trial. Blood 88:347a, 1996 (abstr, suppl 1)
150. Kyle RA: Multiple myeloma. Review of 869 cases. Mayo Clin Proc 50:29, 1975
151. Beguin Y, Yerna M, Loo M, Weber M, Fillet G: Erythropoiesis in multiple myeloma: Defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82:648, 1992
152. Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693, 1990
153. Garton GP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, Kyle RA: Epoetin alfa for the treatment of the anemia of multiple myeloma. Arch Intern Med 155:2069, 1995
154. Österborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jäger G, Najman A, Peest D: Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study. Blood 87:2675, 1996
155. Cazzola M, Barosi G, Gobbi PG, Invernizzi R, Riccardi A, Ascari E: Natural history of idiopathic refractory sideroblastic anemia. Blood 71:305, 1988
156. Martelli M, Ponchio L, Beguin Y, Meloni G, Mandelli F, Cazzola M: Pure red cell aplasia following peripheral stem cell transplantation: Complete response to a short course of high-dose recombinant human erythropoietin. Haematologica 79:456, 1994
157. Stenke L, Wallvik J, Celsing F, Hast R: Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 7:1324, 1993
158. Hellström-Lindberg E: Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67, 1995
159. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L: The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89:831, 1995
160. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL: Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor in combination with erythropoietin. Blood 82:737, 1993
161. Hellström-Lindberg E, Birgegård G, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen JM, Winquist I, Öst Å: A combination of granulocyte-colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221, 1993
162. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human erythropoietin: Evidence for in vivo synergy. Blood 87:4076, 1996
163. Tefferi A, Silverstein MN: Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia (letter). Br J Haematol 86:893, 1994
164. Beguin Y, Clemons GK, Oris R, Fillet G: Circulating erythropoietin after bone marrow transplantation: Inappropriate response to anemia in allogeneic transplants. Blood 77:868, 1991
165. Locatelli L, Zecca M, Beguin Y, Giorgiani G, Ponchio L, De Stefano P, Cazzola M: Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation. Br J Haematol 84:752, 1993
166. Klaesson S, Ringdén O, Ljungman P, Lönnqvist B, Wennberg L: Reduced blood transfusion requirements after allogeneic bone marrow transplantation: Results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 13:397, 1994
167. Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC, Carella AM, Mandelli F, Burdach S, Ferrant A, Linkesch W, Tura S, Bacigalupo A, Schindel F, Heinrichs H: A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 84:3327, 1994
168. Biggs JC, Atkinson KA, Booker V, Concannon A, Dart GW, Dodds A, Downs K, Szer J, Turner J, Worthington R: Prospective ndomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant 15:129, 1995
169. Locatelli F, Zecca M, Pedrazzoli P, Prete L, Quaglini S, Comoli P, De Stefano P, Beguin Y, Robustelli della Cuna G, Severi F, Cazzola M: Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: Effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 13:403, 1994
170. Pirelli L, Scambia G, Menichella G, d'Onofrio G, Salerno G, Benedetti Panici P, Foddai ML, Vittori M, Lai M, Ciarli M, Puglia G, Mancuso S, Bizzi B: The combination of erythroid and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor transplantation. Br J Haematol 92:287, 1996
171. Mitus AJ, Antin JH, Rutherford CJ, McGarigle CJ, Goldberg MA: Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs. Blood 83:1952, 1994
172. Sherwood JB, Goldwasser E, Chilcote R, Carmichael LD, Nagel RL: Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 67:46, 1986
173. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF: Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 323:366, 1990
174. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW: Augmentation by erythropoietin of the fetal-moglobin response to hydroxyurea in sickle cell disease. N Engl J Med 328:73, 1993
175. Steinberg MH: Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med 324:1369, 1991 (letter)
176. Galanello R, Barella S, Turco MP, Giagu N, Cao A, Dore F, Liberato NL, Guarnone R, Barosi G: Serum erythropoietin and erythropoiesis in high and low-fetal hemoglobin β-thalassemia intermedia patients. Blood 83:561, 1994
177. Olivieri NF, Freedman MH, Perrine SP, Dover GJ, Sheridan B, Essentine DL, Nagel RL: Trial of recombinant human erythropoietin: Three patients with thalassemia intermedia. Blood 80:3258, 1992 (letter)
178. Rachmilewitz EA, Aker M, Perry D, Dover G: Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. Br J Haematol 90:341, 1995
179. Locatelli F, Zecca M, Mamprin F, Gamba A, Giorgiani G, De Stefano P: Recombinant human erythropoietin may correct erythropoietin-deficient hyporegenerative anaemia in children given cardiac transplantation. Br J Haematol 88:623, 1994
180. Hoeldtke RD, Streeten D: Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 329:611, 1993
181. Barosi G, Cazzola M, De Vincentiis A, Grossi A, Tura S: Guidelines for the use of recombinant human erythropoietin. Haematologica 79:526, 1994
182. Ludwig H, Fritz E, Leitgeb C, Percherstorfer M, Samonigg H, Schuster J: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056, 1994